迪哲医药-U
(688192)
| 流通市值：260.63亿 | | | 总市值：265.18亿 |
| 流通股本：4.53亿 | | | 总股本：4.61亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 586,301,134.9 | 355,001,420.82 | 159,641,464.34 | 359,900,621.06 |
| 营业收入 | 586,301,134.9 | 355,001,420.82 | 159,641,464.34 | 359,900,621.06 |
| 二、营业总成本 | 1,234,483,936.24 | 779,607,061.37 | 382,021,501.25 | 1,356,850,887.84 |
| 营业成本 | 25,325,157.63 | 15,627,388.07 | 7,071,641.67 | 9,316,308.61 |
| 税金及附加 | 2,204,553.79 | 1,181,663.24 | 379,400.3 | 2,040,790.21 |
| 销售费用 | 423,739,702.55 | 268,437,718.75 | 123,552,561.58 | 445,331,190.18 |
| 管理费用 | 116,279,108.6 | 69,705,766.61 | 32,502,067.44 | 153,445,761.53 |
| 研发费用 | 644,235,609.66 | 408,267,006.28 | 210,333,356.42 | 723,687,401.43 |
| 财务费用 | 22,699,804.01 | 16,387,518.42 | 8,182,473.84 | 23,029,435.88 |
| 其中:利息费用 | 23,591,119.1 | 17,152,091.02 | 8,495,528.4 | 22,754,524.23 |
| 其中:利息收入 | 1,840,889.36 | 1,459,518.03 | -562,288.47 | 2,242,276.01 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 18,554,239.98 | 11,219,000.56 | 3,607,839.77 | 14,450,692.6 |
| 资产处置收益 | 279.52 | 279.52 | - | - |
| 信用减值损失(新) | -1,006,159.94 | -551,953.94 | -211,372.94 | 118,259.17 |
| 其他收益 | 47,733,361.57 | 34,947,986.41 | 25,242,840.17 | 41,080,270.13 |
| 四、营业利润 | -582,901,080.21 | -378,990,328 | -193,740,729.91 | -941,301,044.88 |
| 加:营业外收入 | - | - | - | 1,652,961 |
| 减:营业外支出 | - | - | - | 3,253.32 |
| 五、利润总额 | -582,901,080.21 | -378,990,328 | -193,740,729.91 | -939,651,337.2 |
| 减:所得税费用 | 52,072.14 | 52,072.14 | - | 3,851.5 |
| 六、净利润 | -582,953,152.35 | -379,042,400.14 | -193,740,729.91 | -939,655,188.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -582,953,152.35 | -379,042,400.14 | -193,740,729.91 | -939,655,188.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -579,947,780.97 | -377,360,125.54 | -192,513,348.95 | -845,956,285.93 |
| 少数股东损益 | -3,005,371.38 | -1,682,274.6 | -1,227,380.96 | -93,698,902.77 |
| 扣除非经常损益后的净利润 | -630,660,904.63 | -419,231,317.05 | -219,485,211.62 | -898,889,978.56 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -1.32 | -0.87 | -0.46 | -2.04 |
| (二)稀释每股收益 | -1.32 | -0.87 | -0.46 | -2.04 |
| 九、综合收益总额 | -582,953,152.35 | -379,042,400.14 | -193,740,729.91 | -939,655,188.7 |
| 归属于母公司股东的综合收益总额 | -579,947,780.97 | -377,360,125.54 | -192,513,348.95 | -845,956,285.93 |
| 归属于少数股东的综合收益总额 | -3,005,371.38 | -1,682,274.6 | -1,227,380.96 | -93,698,902.77 |
| 公告日期 | 2025-10-31 | 2025-08-23 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |